New data support apixaban over rivaroxaban for newly diagnosed VTE
KEY POINT
Use of apixaban (Eliquis—Bristol–Myers Squibb, Pfizer) appears to be more effective than rivaroxaban (Xarelto—Janssen) for prevention of recurrent venous thromboembolism (VTE) with a decreased risk of major bleeding events, according to results of a retrospective, observational study published in The Lancet Haematology.
SOURCES
Dawwas GK, et al. Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis. Lancet Haematol. 2019;6(1):e20–8.
Frere C, et al. The best direct-acting oral anticoagulant for treatment of venous thromboembolism. Lancet Haematol. 2019;6(1):e4–5.
